IGC Pharma, Inc. (IGC)

Market Cap	25.38M
Revenue (ttm)	1.27M
Net Income (ttm)	-7.12M
Shares Out	83.89M
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	240,572
Open	0.3086
Previous Close	0.3070
Day's Range	0.3025 - 0.3113
52-Week Range	0.2525 - 0.4980
Beta	1.48
Analysts	Strong Buy
Price Target	3.88 (+1,182.65%)
Earnings Date	Jun 27, 2025

About IGC

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer’s disease. The company’s lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer’s; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 67
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: IGC
• Website: https://igcpharma.com

Financial Performance

In 2024, IGC Pharma's revenue was $1.27 million, a decrease of -5.50% compared to the previous year's $1.35 million. Losses were -$7.12 million, -45.22% less than in 2023.

Analyst Summary

According to 2 analysts, the average rating for IGC stock is "Strong Buy." The 12-month stock price target is $3.88, which is an increase of 1,182.65% from the latest price.

Price Target

$3.88

(1,182.65% upside)

Analyst Consensus: Strong Buy